Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.

Détails

ID Serval
serval:BIB_F31099178815
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort.
Périodique
European journal of gastroenterology & hepatology
Auteur(s)
Godat S., Fournier N., Safroneeva E., Juillerat P., Nydegger A., Straumann A., Vavricka S., Biedermann L., Greuter T., Fraga M., Abdelrahman K., Hahnloser D., Sauter B., Rogler G., Michetti P., Schoepfer A.M.
Collaborateur(s)
Swiss IBD Cohort Study Group
ISSN
1473-5687 (Electronic)
ISSN-L
0954-691X
Statut éditorial
Publié
Date de publication
06/2018
Peer-reviewed
Oui
Volume
30
Numéro
6
Pages
612-620
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study
Publication Status: ppublish
Résumé
Systematic analyses of inflammatory bowel disease (IBD) drug-related side effects necessitating treatment cessation in large cohorts of patients with IBD are scarce. We aimed to assess the frequency and type of drug-related side effects requiring drug cessation in patients included in the Swiss IBD Cohort.
A retrospective review was performed of data from the Swiss IBD Cohort physician questionnaires documenting a treatment cessation for the following drug categories: aminosalicylates, topical and systemic steroids, thiopurines, methotrexate, tumor necrosis factor-antagonists, and calcineurin inhibitors (tacrolimus, cyclosporine).
A total of 3192 patients were analyzed, of whom 1792 (56.1%) had Crohn's disease, 1322 (41.4%) had ulcerative colitis, and 78 (2.5%) had IBD unclassified. Of 3138 patients treated with IBD drugs, 2129 (67.8%) presented with one or several drug-related side effects necessitating drug cessation. We found a significant positive correlation between the number of concomitantly administered IBD drugs and the occurrence of side effects requiring drug cessation (P<0.001). Logistic regression modeling identified Crohn's disease diagnosis [odds ratio (OR)=1.361, P=0.017], presence of extraintestinal manifestations (OR=2.262, P<0.001), IBD-related surgery (OR=1.419, P=0.006), and the increasing number of concomitantly used IBD drugs [OR=2.007 (P<0.001) for two concomitantly used IBD drugs; OR=3.225 (P<0.001) for at least three concomitantly used IBD drugs] to be associated significantly with the occurrence of IBD drug-related adverse events that necessitated treatment cessation.
Physicians should keep in mind that the number of concomitantly administered IBD drugs is the main risk factor for drug-related adverse events necessitating treatment cessation.
Mots-clé
Adolescent, Adult, Adverse Drug Reaction Reporting Systems, Aged, Aged, 80 and over, Anti-Inflammatory Agents/adverse effects, Chi-Square Distribution, Child, Child, Preschool, Colitis, Ulcerative/diagnosis, Colitis, Ulcerative/drug therapy, Colitis, Ulcerative/epidemiology, Crohn Disease/diagnosis, Crohn Disease/drug therapy, Crohn Disease/epidemiology, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions/diagnosis, Drug-Related Side Effects and Adverse Reactions/epidemiology, Female, Gastrointestinal Agents/adverse effects, Humans, Infant, Logistic Models, Male, Middle Aged, Multivariate Analysis, Odds Ratio, Retrospective Studies, Risk Factors, Switzerland/epidemiology, Young Adult
Pubmed
Web of science
Création de la notice
01/02/2018 17:27
Dernière modification de la notice
07/10/2019 14:53
Données d'usage